# OnCo record paper-keynote-966-lancet-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-966-lancet-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-966-lancet-2023" ;
  schema:name "KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer"@en ;
  schema:description "Adding pembrolizumab to gemcitabine-cisplatin, with gemcitabine continued as maintenance, lengthened survival in advanced biliary tract cancer by about two months, confirming the role of chemo-immunotherapy shown by TOPAZ-1."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-966-lancet-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(23)00727-4>, <https://pubmed.ncbi.nlm.nih.gov/37075781/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(23)00727-4> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Kelley RK, Ueno M, Yoo C, et al." ;
  onco:cancers <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/keynote-966/> ;
  onco:journals <https://onco.cc/journals/lancet/> .